1. Dynamic changes in circulating EBV-DNA load during treatment have prognostic values in EBV+ DLBCL-NOS: a Chinese cohort study.
- Author
-
Xing, Tong-Yao, Duan, Zi-Wen, Wang, Wei-Ting, Du, Kai-Xin, Shen, Hao-Rui, Yin, Hua, Wu, Jia-Zhu, Li, Yue, Wang, Li, Li, Jian-Yong, Liang, Jin-Hua, and Xu, Wei
- Subjects
CIRCULATING tumor DNA ,PROGNOSIS ,DIFFUSE large B-cell lymphomas ,CHINA studies ,EPSTEIN-Barr virus diseases ,PROGRESSION-free survival ,COHORT analysis - Abstract
EBV-positive diffuse large B-cell lymphoma, not otherwise specified (EBV
+ DLBCL-NOS), is an EBV-positive clonal B-cell lymphoid proliferation and circulating EBV-DNA is a great indicator for prognosis among EBV associated disease. In this retrospective study, we report 66 EBV+ DLBCL cases among 2137 DLBCL-NOS cases diagnosed from 2013 to 2021 (prevalence of 6.0%). After a median follow-up of 27 months, progression-free survival (PFS) and overall survival (OS) at 2 years were 39.5% ± 6.2% and 53.6% ± 6.4%, respectively. Multivariate analysis showed that only the biomarker of the positivity of post treatment EBV-DNA had a borderline correlation with shorter PFS and OS (PFS: P = 0.053; OS: P = 0.065). Patients were divided into three subgroups according to dynamic changes of EBV-DNA status: EBV-DNA persistently negative group, EBV-DNA persistently positive group, and EBV-DNA transformed from positive to negative group; among the three groups, patients of the persistently positive group had worst PFS and OS (P = 0.0527 and P = 0.0139, respectively). Decline in EBV copies correlated significantly with treatment response as well. In conclusion, circulating EBV-DNA level played a vital role in prognostic and monitoring marker for EBV+ DLBCL-NOS. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF